Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: Part III. Ethical considerations
- 31 October 2002
- journal article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 12, S52-S54
- https://doi.org/10.1016/s0960-8966(02)00099-8
Abstract
No abstract availableKeywords
This publication has 2 references indexed in Scilit:
- Therapeutic possibilities in muscular dystrophy: the hope versus the hypeNeuromuscular Disorders, 2002
- Gene therapy: regulatory issues and international approaches to regulationCurrent Opinion in Biotechnology, 1997